Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Qingsheng Xu (17078830) (author)
Andere auteurs:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items